Biogen’s ALS drug gets European Commission’s marketing nod
The European Commission has granted marketing approval for Biogen Inc.’s therapy for the treatment of a form of amyotrophic lateral sclerosis.
Drugs
Health
Pharma
Drugs
Health
Pharma
European regulator backs Biogen’s drug for amyotrophic lateral sclerosis
HQ Team February 24, 2024: Biogen Inc., a US biotechnology company, has got marketing authorisation from the European medicines regulator for its drug.